nodes	percent_of_prediction	percent_of_DWPC	metapath
Orphenadrine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.205	0.419	CbGbCtD
Orphenadrine—CYP3A4—Cytarabine—lymphatic system cancer	0.09	0.184	CbGbCtD
Orphenadrine—CYP3A4—Teniposide—lymphatic system cancer	0.0887	0.182	CbGbCtD
Orphenadrine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.062	0.127	CbGbCtD
Orphenadrine—Urinary hesitation—Fludarabine—lymphatic system cancer	0.0545	0.107	CcSEcCtD
Orphenadrine—CYP3A4—Vincristine—lymphatic system cancer	0.0427	0.0874	CbGbCtD
Orphenadrine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0123	0.0241	CcSEcCtD
Orphenadrine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.012	0.0234	CcSEcCtD
Orphenadrine—Agitation—Teniposide—lymphatic system cancer	0.0102	0.02	CcSEcCtD
Orphenadrine—Confusional state—Teniposide—lymphatic system cancer	0.00916	0.0179	CcSEcCtD
Orphenadrine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00908	0.0177	CcSEcCtD
Orphenadrine—Agitation—Fludarabine—lymphatic system cancer	0.00899	0.0176	CcSEcCtD
Orphenadrine—Tachycardia—Teniposide—lymphatic system cancer	0.00886	0.0173	CcSEcCtD
Orphenadrine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00872	0.017	CcSEcCtD
Orphenadrine—Confusional state—Fludarabine—lymphatic system cancer	0.00805	0.0157	CcSEcCtD
Orphenadrine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00798	0.0156	CcSEcCtD
Orphenadrine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00783	0.0153	CcSEcCtD
Orphenadrine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00748	0.0146	CcSEcCtD
Orphenadrine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00745	0.0145	CcSEcCtD
Orphenadrine—Nausea—Mechlorethamine—lymphatic system cancer	0.00732	0.0143	CcSEcCtD
Orphenadrine—Urticaria—Teniposide—lymphatic system cancer	0.00722	0.0141	CcSEcCtD
Orphenadrine—Hallucination—Carmustine—lymphatic system cancer	0.00715	0.014	CcSEcCtD
Orphenadrine—Hallucination—Vincristine—lymphatic system cancer	0.00683	0.0133	CcSEcCtD
Orphenadrine—Constipation—Fludarabine—lymphatic system cancer	0.00683	0.0133	CcSEcCtD
Orphenadrine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00669	0.0131	CcSEcCtD
Orphenadrine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00658	0.0128	CcSEcCtD
Orphenadrine—Asthenia—Teniposide—lymphatic system cancer	0.00652	0.0127	CcSEcCtD
Orphenadrine—Pruritus—Teniposide—lymphatic system cancer	0.00643	0.0126	CcSEcCtD
Orphenadrine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00623	0.0122	CcSEcCtD
Orphenadrine—Confusional state—Bleomycin—lymphatic system cancer	0.0059	0.0115	CcSEcCtD
Orphenadrine—Vision blurred—Carmustine—lymphatic system cancer	0.0059	0.0115	CcSEcCtD
Orphenadrine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00588	0.0115	CcSEcCtD
Orphenadrine—Tremor—Carmustine—lymphatic system cancer	0.00586	0.0115	CcSEcCtD
Orphenadrine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00585	0.0114	CcSEcCtD
Orphenadrine—Vomiting—Teniposide—lymphatic system cancer	0.00577	0.0113	CcSEcCtD
Orphenadrine—Agitation—Carmustine—lymphatic system cancer	0.00575	0.0112	CcSEcCtD
Orphenadrine—Asthenia—Fludarabine—lymphatic system cancer	0.00573	0.0112	CcSEcCtD
Orphenadrine—Headache—Teniposide—lymphatic system cancer	0.00569	0.0111	CcSEcCtD
Orphenadrine—Pruritus—Fludarabine—lymphatic system cancer	0.00565	0.011	CcSEcCtD
Orphenadrine—Agitation—Vincristine—lymphatic system cancer	0.00549	0.0107	CcSEcCtD
Orphenadrine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00548	0.0107	CcSEcCtD
Orphenadrine—Nausea—Teniposide—lymphatic system cancer	0.00539	0.0105	CcSEcCtD
Orphenadrine—Confusional state—Carmustine—lymphatic system cancer	0.00515	0.0101	CcSEcCtD
Orphenadrine—Vomiting—Fludarabine—lymphatic system cancer	0.00508	0.00991	CcSEcCtD
Orphenadrine—Headache—Fludarabine—lymphatic system cancer	0.005	0.00977	CcSEcCtD
Orphenadrine—Tachycardia—Carmustine—lymphatic system cancer	0.00499	0.00974	CcSEcCtD
Orphenadrine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00488	0.00953	CcSEcCtD
Orphenadrine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00482	0.00942	CcSEcCtD
Orphenadrine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00479	0.00936	CcSEcCtD
Orphenadrine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00475	0.00928	CcSEcCtD
Orphenadrine—Nausea—Fludarabine—lymphatic system cancer	0.00474	0.00926	CcSEcCtD
Orphenadrine—Urticaria—Bleomycin—lymphatic system cancer	0.00465	0.00908	CcSEcCtD
Orphenadrine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00464	0.00906	CcSEcCtD
Orphenadrine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00461	0.00901	CcSEcCtD
Orphenadrine—Somnolence—Carmustine—lymphatic system cancer	0.00454	0.00887	CcSEcCtD
Orphenadrine—Constipation—Carmustine—lymphatic system cancer	0.00437	0.00853	CcSEcCtD
Orphenadrine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00431	0.00842	CcSEcCtD
Orphenadrine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00422	0.00825	CcSEcCtD
Orphenadrine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00421	0.00822	CcSEcCtD
Orphenadrine—Asthenia—Bleomycin—lymphatic system cancer	0.0042	0.0082	CcSEcCtD
Orphenadrine—Constipation—Vincristine—lymphatic system cancer	0.00417	0.00815	CcSEcCtD
Orphenadrine—Pruritus—Bleomycin—lymphatic system cancer	0.00414	0.00809	CcSEcCtD
Orphenadrine—Constipation—Mitoxantrone—lymphatic system cancer	0.00406	0.00793	CcSEcCtD
Orphenadrine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00391	0.00765	CcSEcCtD
Orphenadrine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00377	0.00737	CcSEcCtD
Orphenadrine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00376	0.00735	CcSEcCtD
Orphenadrine—Vomiting—Bleomycin—lymphatic system cancer	0.00372	0.00727	CcSEcCtD
Orphenadrine—Drowsiness—Methotrexate—lymphatic system cancer	0.00371	0.00725	CcSEcCtD
Orphenadrine—Asthenia—Carmustine—lymphatic system cancer	0.00367	0.00716	CcSEcCtD
Orphenadrine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00359	0.00702	CcSEcCtD
Orphenadrine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0035	0.00684	CcSEcCtD
Orphenadrine—Asthenia—Vincristine—lymphatic system cancer	0.0035	0.00684	CcSEcCtD
Orphenadrine—Nausea—Bleomycin—lymphatic system cancer	0.00348	0.00679	CcSEcCtD
Orphenadrine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00341	0.00666	CcSEcCtD
Orphenadrine—Dizziness—Carmustine—lymphatic system cancer	0.00338	0.0066	CcSEcCtD
Orphenadrine—Vomiting—Carmustine—lymphatic system cancer	0.00325	0.00635	CcSEcCtD
Orphenadrine—Dizziness—Vincristine—lymphatic system cancer	0.00322	0.0063	CcSEcCtD
Orphenadrine—Headache—Carmustine—lymphatic system cancer	0.0032	0.00625	CcSEcCtD
Orphenadrine—Vomiting—Vincristine—lymphatic system cancer	0.0031	0.00606	CcSEcCtD
Orphenadrine—Headache—Vincristine—lymphatic system cancer	0.00306	0.00597	CcSEcCtD
Orphenadrine—Nausea—Carmustine—lymphatic system cancer	0.00303	0.00593	CcSEcCtD
Orphenadrine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00302	0.0059	CcSEcCtD
Orphenadrine—Headache—Mitoxantrone—lymphatic system cancer	0.00298	0.00581	CcSEcCtD
Orphenadrine—Nausea—Vincristine—lymphatic system cancer	0.0029	0.00566	CcSEcCtD
Orphenadrine—Nausea—Mitoxantrone—lymphatic system cancer	0.00282	0.00551	CcSEcCtD
Orphenadrine—Vision blurred—Methotrexate—lymphatic system cancer	0.00273	0.00534	CcSEcCtD
Orphenadrine—Confusional state—Methotrexate—lymphatic system cancer	0.00239	0.00466	CcSEcCtD
Orphenadrine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00237	0.00462	CcSEcCtD
Orphenadrine—Skin disorder—Methotrexate—lymphatic system cancer	0.0023	0.00449	CcSEcCtD
Orphenadrine—Somnolence—Methotrexate—lymphatic system cancer	0.0021	0.00411	CcSEcCtD
Orphenadrine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00195	0.00381	CcSEcCtD
Orphenadrine—Urticaria—Methotrexate—lymphatic system cancer	0.00188	0.00367	CcSEcCtD
Orphenadrine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00174	0.00341	CcSEcCtD
Orphenadrine—Asthenia—Methotrexate—lymphatic system cancer	0.0017	0.00332	CcSEcCtD
Orphenadrine—Pruritus—Methotrexate—lymphatic system cancer	0.00167	0.00327	CcSEcCtD
Orphenadrine—Dizziness—Methotrexate—lymphatic system cancer	0.00156	0.00306	CcSEcCtD
Orphenadrine—Vomiting—Methotrexate—lymphatic system cancer	0.0015	0.00294	CcSEcCtD
Orphenadrine—Headache—Methotrexate—lymphatic system cancer	0.00148	0.0029	CcSEcCtD
Orphenadrine—Nausea—Methotrexate—lymphatic system cancer	0.00141	0.00275	CcSEcCtD
